JAAD-D-21-03349-SupplementalMaterial

SUPPLEMENTAL MATERIAL Supplemental Figure 1. Flowchart Flowchart reporting the clinical profile of DM patients included in the study and the number of patients analyzed at last follow-up. Supplemental Figure 2. Cutaneous improvement to JAK inhibitor in a patient at follow-up Illustrative case (patient 4) with skin refractory dermatomyositis demonstrating a cutaneous response to ruxolitinib. CDASI at baseline was 49 and significantly decreased to 30 at 3-month. Clinical improvement was sustained (CDASI of 26) at 6-month follow-up. Prednisone was decreased from 10 to 7 mg/day over this period of time. Supplemental Figure 3. Manual muscle testing evolution following JAK inhibitor treatment Mean±SD manual MMT8 of 120±31, 121±29, 128±26 and 132±124 at baseline (M0), 3-month, 6-month and last follow-up, respectively. M0: baseline; M3: 3-month; M6: 6-month; FU: follow-up; MMT: manual muscle testing. Data shown as mean±SD Supplemental Figure 4. Treatment burden evolution following JAK inhibitor treatment Percentage of patients remaining with IVIg and/or prednisone 5mg/day at follow-up. IVIg was stopped in 1 patient at 6-month and in 4 patients at last follow-up. Prednisone decrease to ≤5 mg/day was achieved in 1, 2 and 10 patients at 3-month, 6-month and last follow-up, respectively. IVIg: intravenous immunoglobulin; Pred: prednisone; M0: baseline; M3: 3-month; M6: 6-month; FU: follow-up. Data shown as percentage Supplemental Figure 5. IFN alpha at 3 months Non-significant trend of IFN alpha decrease from mean±SD 1612±4316 fg/mL to 1352±3722 fg/mL between baseline and 3-month. IFN: interferon